Navigation Links
DATATRAK Exhibiting at the DIA's 3rd Annual Clinical Forum in Nice, France
Date:10/13/2009

CLEVELAND, Oct. 13 /PRNewswire-FirstCall/ -- DATATRAK International, Inc. (OTCQX: DATA), a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced its attendance at the 3rd Annual Clinical Forum in Nice, France. DATATRAK will be exhibiting in Booth 19 at the Nice Acropolis on October 19-21, 2009.

Visit the booth to see how DATATRAK ONE(TM) technology and services provide the comprehensive and cohesive solution you need for delivering all your clinical trials in one system with one database. We are offering demonstrations that give you a firsthand look at our fast reporting, unrivaled stability and enhanced usability. If you would like to schedule a personal demonstration during the show, please send an email to marketing@datatrak.net.

About DIA 3rd Annual Clinical Forum.

Join new and experienced colleagues in the field of clinical and safety data management, statistics, medical information, medical writing, pharmacovigilance, information technology and validation in attending a wide range of educational forums, discuss experiences and uncover solutions. For more information on the DIA's 3rd Annual Clinical Forum, see http://www.diahome.org/

About DATATRAK International, Inc.

DATATRAK International, Inc. is a worldwide technology and services company focused on the provision of multi-component eClinical solutions and related services for the clinical trials industry. We operate under the concept of DATATRAK ONE(TM), which encompasses our unique, single platform technology. The singular architecture of our DATATRAK eClinical(TM) product suite has been embraced by clients around the globe for its ability to effectively manage clinical trials through a unified multi-component, comprehensive solution. The Company delivers a complete portfolio of software products that were created in order to accelerate clinical research data from investigative sites to clinical trial sponsors and ultimately the FDA, faster and more efficiently than manual methods or loosely integrated technologies. DATATRAK's eClinical(TM) software suite can be deployed worldwide through an ASP offering or in a licensed Enterprise Transfer model that fully empowers its clients. The DATATRAK software suite and its earlier versions have successfully supported hundreds of international clinical trials involving thousands of clinical research sites and encompassing tens of thousands of patients in 59 countries. DATATRAK International, Inc.'s product suite has been utilized in some aspect of the clinical development of 16 drugs and one medical device that have received regulatory approval from either the United States Food and Drug Administration or counterpart European bodies. DATATRAK International, Inc. has offices located in Cleveland, Ohio, and Bryan, Texas. Visit the DATATRAK International, Inc. web site at www.datatrak.net.

Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management's expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors (including those specified below) which are difficult to predict and, in many instances, are beyond the control of the Company. Factors that may cause actual results to differ materially from those in the forward-looking statements include the limited operating history on which the Company's performance can be evaluated; the ability of the Company to continue to enhance its software products to meet customer and market needs; fluctuations in the Company's quarterly results; the viability of the Company's business strategy and its early stage of development; the timing of clinical trial sponsor decisions to conduct new clinical trials or cancel or delay ongoing trials; the Company's dependence on major customers; government regulation associated with clinical trials and the approval of new drugs; the ability of the Company to compete in the emerging EDC market; losses that potentially could be incurred from breaches of contracts or loss of customer data; the inability to protect intellectual property rights or the infringement upon other's intellectual property rights; the costs associated with maintaining and/or developing two product suites; and general economic conditions such as the rate of employment, inflation, interest rates and the condition of capital markets. This list of factors is not all-inclusive. In addition, the Company's success depends on the outcome of various strategic initiatives it has undertaken, all of which are based on assumptions made by the Company concerning trends in the clinical research market and the health care industry. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.

SOURCE DATATRAK International, Inc.


'/>"/>
SOURCE DATATRAK International, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. DATATRAK Launches New Web Site
2. Advance Research Associates Joins DATATRAKs CRO Connect Program(TM)
3. DATATRAK Announces New Products and Features at DIA San Diego
4. DATATRAK Announces Receipt of NASDAQ Panel Decision to Delist Common Shares
5. DATATRAK International, Inc. Announces First Quarter Results for 2009
6. German CRO clinicalprojects international GmbH Becomes Newest Member of DATATRAKs CRO Connect Program(TM)
7. Keypoint Joins DATATRAKs CRO Connect Program(TM)
8. NASDAQ Panel Grants Extension to DATATRAK for Continued Listing on the NASDAQ Capital Market
9. DATATRAK International, Inc. Announces Fourth Quarter and Full Year Results for 2008
10. DATATRAK International, Inc. Announces the Return of Chris Wilke as Vice-President of R&D and the Issuance of a Patent
11. DATATRAK Announces Retirement of Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... Intellitec Solutions is ... of Microsoft Dynamics GP for one their long-term care clients. Working together with ... GP with key clinical management systems, and delivered a fully integrated accounting and ...
(Date:4/29/2016)... ... April 29, 2016 , ... Pro3rd Grunge is a package of 30 grunge-themed ... to introduce people, characters, and locations without having to set a single keyframe. Choose ... many more design components. Simply select a preset and drag it into the ...
(Date:4/29/2016)... ... April 29, 2016 , ... In its efforts of bringing quality ... its successful franchise development and expansion as it welcomes Ferdie Vasquez of the new ... experience in his 32 years of working in various industries. He had been ...
(Date:4/28/2016)... St. Petersburg, FL (PRWEB) , ... April 29, 2016 , ... Sublime Beauty® is offering ... of the same product) for 50% off. The discount is applied to the product with ... box is given to those who purchase $250 or more in products. , "So many ...
(Date:4/28/2016)... ... 28, 2016 , ... ProText Layouts is a set of 30 self-animating kinetic ... With ProText Layouts, video editors can create an energetic typography video with incredible ease. ... texts. Creating text-based videos have never been easier. , ProText Layouts includes 30 ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... 28, 2016 , Net Sales of $1.90 ... over the prior year period, and an increase of 1.2% ... Diluted EPS for the first quarter were $0.52 reported, a ... adjusted, an increase of 29.9% over the prior year period ... earnings guidance for 2016 Zimmer Biomet Holdings, Inc. ...
(Date:4/28/2016)... Calif. , April 28, 2016 /PRNewswire/ ... Validation Lifecycle Management Solutions (VLMS) today announced ... and services for sufferers of chronic kidney ... System to manage their corporate validation process. ... seeking a software solution to manage their ...
(Date:4/27/2016)... , Schweiz, April 27, 2016 ... Sachs CEO Forums in Zürich gab Strekin ... führenden Wirkstoffkandidaten STR001 zur Erhaltung des Resthörvermögens ... wurde, bekannt. Für die umfassende Phase-II-Doppelblindstudie mit ... Frankreich angeworben. STR001 wird während der Operation ...
Breaking Medicine Technology: